Pregabalin
Product Images NDC 45865-126

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 45865-126). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Medsource Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pregabalin Capsules 100 mg (Pdp 126)

Pregabalin Capsules 100 mg label from Medsource Pharmaceuticals, generic for Lyrica. The label indicates lot number 45865-0126-30 with a hashtag #30, displaying usage instructions to take one or more capsules daily as directed by a physician. The label includes a warning about dizziness and a notice restricting drug transfer to the prescribed patient only.*

FDA Label Image

Figure 1 (Pregabalin Fig01)

A line graph depicting the percent of patients improved against the percent improvement in pain from baseline for Pregabalin doses of 25 mg, 100 mg, and 200 mg taken three times a day, compared to placebo. The graph shows multiple descending curves representing each treatment group's performance on pain improvement.*

FDA Label Image

Figure 2 (Pregabalin Fig02)

A line graph comparing the percent of patients improved based on percent improvement in pain from baseline. It shows two lines representing Pregabalin 100 mg three times a day and placebo, with the y-axis labeled percent of patients improved and the x-axis labeled percent improvement in pain from baseline.*

FDA Label Image

Figure 3 (Pregabalin Fig03)

A line chart showing the percent of patients improved versus percent improvement in pain from baseline for Pregabalin at doses of 75 mg, 150 mg, and 300 mg taken twice a day, compared to placebo. The chart depicts improvement trends with increasing pain relief percentages, with separate lines for each dose and placebo.*

FDA Label Image

Figure 4 (Pregabalin Fig04)

A line graph showing percent improvement in pain from baseline on the x-axis and percent of patients improved on the y-axis. The graph compares Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo groups, illustrating higher patient improvement percentages with increased Pregabalin dosage.*

FDA Label Image

Figure 5 (Pregabalin Fig05)

A line graph illustrating percent improvement in pain from baseline versus percent of patients improved. It compares three groups: Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo, showing trends across varying levels of pain improvement.*

FDA Label Image

Figure 6 (Pregabalin Fig06)

A bar graph showing responder rate percentages from two studies, Study E1 and Study E3. Study E1 compares placebo and four Pregabalin BID doses (50 mg/day, 150 mg/day, 300 mg/day, 600 mg/day), showing increasing responder rates with higher doses. Study E3 compares placebo, Pregabalin 300 mg/day BID, and 600 mg/day TID, with higher responder rates at the increased doses. A note indicates statistical significance versus placebo.*

FDA Label Image

Figure 7 (Pregabalin Fig07)

A line graph showing seizure reduction as median percent change from baseline versus dose in mg/day for Pregabalin studies. Four study groups are plotted, including Study E1 (BD), Study E2 (TID), Study E3 (BD), and Study E3 (TID). Significant p-values are indicated, highlighting seizure reduction trends with increasing dose.*

FDA Label Image

Figure 9 (Pregabalin Fig08)

A line chart showing the percent of patients improved versus percent improvement in pain from baseline. It compares four groups: Pregabalin 800 mg daily dose, Pregabalin 450 mg daily dose, Pregabalin 300 mg daily dose, and placebo. The chart illustrates the relative effectiveness of different Pregabalin doses compared to placebo over increasing pain improvement percentages.*

FDA Label Image

Figure 10 (Pregabalin Fig09)

A Kaplan-Meier survival curve graph comparing the estimated percentage of subjects without LTR (loss to response) over 180 days between Pregabalin and placebo groups. The y-axis shows the estimated percentage of subjects without LTR from 0% to 100%, and the x-axis represents days from 0 to 180. Pregabalin group is shown with a solid line, and placebo with a dashed line.*

FDA Label Image

Figure 11 (Pregabalin Fig10)

A line graph depicting the percent of subjects improved from baseline to week 12 BOCF with Pregabalin versus Placebo. The x-axis shows the percent improvement, and the y-axis shows the percent of subjects improved. Two lines compare the effectiveness of Pregabalin (solid line) and Placebo (dashed line) across improvement percentages.*

FDA Label Image

Figure 12 (Pregabalin Fig11)

A line graph comparing the percentage of subjects improved at various levels of improvement from baseline to week 16 in a study. The x-axis represents percent improvement from baseline to week 16 BOCF, ranging from greater than 0 to 100 percent. The y-axis represents the percent of subjects improved, from 0 to 100 percent. Two lines are shown: a solid line for Pregabalin and a dotted line for Placebo, with Pregabalin consistently demonstrating higher percentages of subjects improved across the range.*

FDA Label Image

Cockcroft And Gault Equation (Pregabalin Formula)

A formula for calculating creatinine clearance (CLcr) based on age, weight, and serum creatinine, with an adjustment factor for female patients. It shows the equation clearly with respective variables and multiplication by 0.85 for females.*

FDA Label Image

Chemical Structure (Pregabalin Str)

Chemical structure of Pregabalin, showing its molecular arrangement with carbon, hydrogen, amino, and carboxyl groups depicted in a two-dimensional format.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.